The Mechanisms and Clinical Potential of the Mediterranean Diet in the Management of Inflammatory Bowel Disease
DOI:
https://doi.org/10.54097/fgckkj54Keywords:
Inflammatory bowel disease; Mediterranean diet; gut microbiota; immune modulation; intestinal barrier; anti-inflammatory diet; randomized controlled trial; nutritional therapy.Abstract
Inflammatory bowel disease (IBD), including Crohn’s disease (CD)and ulcerative colitis (UC), is a chronic, relapsing, immune-mediated disorder. With the increasing global incidence of IBD, traditional pharmacological therapies face limitations in both efficacy and safety, prompting growing interest in dietary interventions as adjunctive management strategies. The Mediterranean diet (MD), rich in plant-based foods, olive oil, fish, and natural antioxidants, has been shown to exert anti-inflammatory, immunomodulatory, and gut microbiota-regulating effects. This study explores the nutritional composition and anti-inflammatory mechanisms of the MD, its potential in modulating the gut microbiota, immune responses, and intestinal barrier function, and reviews clinical evidence from observational studies and randomized controlled trials. Although MD demonstrates promising effects in reducing disease activity and improving quality of life, the lack of standardized interventions, marked individual variability, and limited evidence on long-term efficacy remain challenges. Future research should focus on developing culturally adapted dietary protocols, elucidating individualized response mechanisms through multi-omics approaches, and integrating MD with functional nutrients or lifestyle interventions to promote its clinical translation and widespread application in IBD.
Downloads
References
[1] Kaplan GG, Windsor JW, et al. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66.
[2] Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–78.
[3] Hou JK, Lee D, Lewis J, et al. Diet and inflammatory bowel disease: review of patient-targeted recommendations. Clin Gastroenterol Hepatol. 2014;12(10):1592–600.
[4] Ananthakrishnan AN. Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci. 2015;60(2):290–8.
[5] Christ A, Lauterbach M, Latz E, et al. Western diet and the immune system: an inflammatory connection. Nat Rev Immunol. 2019;19(3):143–55.
[6] Godny L, Yavne Y, Cohen NA, et al. Mediterranean diet and inflammatory bowel disease. Gut. 2019;68(7):1239.
[7] Bach-Faig A, Berry EM, Lairon D, et al. Mediterranean diet pyramid today. Public Health Nutr. 2011;14(12A):2274–84.
[8] Fundación Dieta Mediterránea. Mediterranean diet pyramid: a lifestyle for today. 2010 edition. Barcelona: MedDiet Foundation; 2011 [cited 2025 Jul 25]. Available from: https://dietamediterranea.com
[9] Ros E. Health benefits of nut consumption. Nutrients. 2010;2(7):652–82.
[10] Makki K, Deehan EC, Walter J, et al. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23(6):705–15.
[11] Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation. Front Immunol. 2019;10:277.
[12] Dinu M, Pagliai G, Casini A, et al. Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score. Eur J Clin Nutr. 2018;72(1):30–43.
[13] De Filippis F, Pellegrini N, Vannini L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016;65(11):1812–21.
[14] Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14(10):573–84.
[15] Haro C, Montes-Borrego M, Rangel-Zúñiga OA, et al. Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. Front Microbiol. 2016;7:907.
[16] Sánchez-Tapia M, Tovar AR, Torres N, et al. Diet as regulator of gut microbiota and its role in health and disease. Arch Med Res. 2020;51(3):183–95.
[17] Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119.
[18] Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids—at the crossroads between the gut microbiota and host metabolism. Nat Rev Gastroenterol Hepatol. 2021;18(5):289–305.
[19] Tosti V, Bertozzi B, Fontana L, et al. Health benefits of the Mediterranean diet: metabolic and molecular mechanisms. J Gerontol A Biol Sci Med Sci. 2018;73(3):318–26.
[20] López de las Hazas MC, Crespo MC, Tomé-Carneiro J, et al. Hydroxytyrosol modulates inflammation, oxidative stress and epigenetic gene regulation in human peripheral blood mononuclear cells. J Funct Foods. 2016;26:295–305.
[21] Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–73.
[22] Rodríguez-Nogales A, Algieri F, de Madaria E, et al. Polyphenols: a promising nutraceutical approach against inflammatory bowel disease. Trends Food Sci Technol. 2018;75:66–84.
[23] Papada E, Kaliora AC, Amerikanou C, et al. Effects of Mediterranean diet, curcumin, and resveratrol on mild-to-moderate active ulcerative colitis: a multicenter randomized clinical trial. Nutrients. 2024;16(1):23.
[24] Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–16.
[25] Inoue K, Ritz NL, Lin Y, et al. Adherence to a Mediterranean diet is associated with lower risk of Crohn’s disease and ulcerative colitis: results from a large prospective cohort study. Clin Nutr. 2021;40(6):3435–41.
[26] Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gut. 2014;63(5):776–84.
[27] Chiba M, Tsuji T, Nakane K, et al. High adherence to a semi-vegetarian diet is associated with increased remission in ulcerative colitis: a prospective cohort study. Intest Res. 2020;18(1):71–8.
[28] Marino F, Rispo A, Manguso F, et al. A Mediterranean diet pattern improves intestinal inflammation concomitant with reshaping of the bacteriome in ulcerative colitis: a randomised controlled trial. J Crohns Colitis. 2023;17(5):669–80.
[29] Barberio B, Massimi D, Zingone F, et al. Is the Mediterranean diet in inflammatory bowel diseases ready for prime time? J Can Assoc Gastroenterol. 2024;7(1):41–47.
[30] Román GC, Jackson RE, Gadhia R, et al. Mediterranean diet: The role of long-chain omega-3 fatty acids in anti-inflammation, immunomodulation and prevention of chronic disease. Front Nutr. 2021;8:713657.
[31] Marlow G, van der Werf A, Mackay H, et al. The effect of the Mediterranean diet on inflammatory bowel disease activity: a randomized controlled trial. J Crohns Colitis. 2023;17(6):893–904.
[32] Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90.
[33] Chicco F, Magrì S, Cingolani A, et al. Multidisciplinary management of IBD: Is diet the neglected partner? Nutrients. 2022;14(13):2649.
[34] Limketkai BN, Barrett TA, Pérez-Ramos J, et al. Role of diet in inflammatory bowel disease: current trends and future directions. Curr Treat Options Gastroenterol. 2020;18(3):319–37.
[35] Nguyen GC, Zhang B, Holcroft CA, et al. Patient perspectives on the use of diet in inflammatory bowel disease: Results from a multicenter survey. Clin Gastroenterol Hepatol. 2022;20(1):147–54.
[36] Lewis JD, Abreu MT. Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology. 2017;152(2):398–414.
[37] Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079–94.
[38] Johnson AJ, Vangay P, Al-Ghalith GA, et al. Daily sampling reveals personalized diet–microbiome associations in humans. Cell Host Microbe. 2019;25(6):789–802.e5.
[39] Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosuvastatin for ulcerative colitis: a randomized controlled trial. Inflamm Bowel Dis. 2023;29(1):27–34.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
